← Eichor
Condition: Non Neoplastic Pancreatic Disorder Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Non Neoplastic Pancreatic Disorder

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Phase N/A · 1 location(s) · University of Missouri-Columbia · NCT02838836Activation of Biobank Registry for Bilio-pancreatic Diseases
Phase N/A · 1 location(s) · IRCCS San Raffaele · NCT06552078A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors
Phase 1/Phase 2 · 26 location(s) · Frontier Medicines Corporation · NCT06244771Development of Non-Invasive Prenatal Diagnosis for Single Gene Disorders
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06147414A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Blueprint Medicines Corporation · NCT07629960A Study of MGC026 in Participants With Advanced Solid Tumors
Phase 1 · 12 location(s) · MacroGenics · NCT06242470Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Tasca Therapeutics · NCT07030257A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Met
Phase 1/Phase 2 · 3 location(s) · GI Innovation, Inc. · NCT07172802Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
Phase N/A · 1 location(s) · M.D. Anderson Cancer Center · NCT03048266Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a
Phase 1/Phase 2 · 6 location(s) · Phanes Therapeutics · NCT05431270A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-8989 in Patien
Phase 1/Phase 2 · 1 location(s) · Shenzhen Ionova Life Sciences Co., Ltd. · NCT07610798A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
Phase 1 · 12 location(s) · Alterome Therapeutics, Inc. · NCT06835569Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C M
Phase 1/Phase 2 · 53 location(s) · Revolution Medicines, Inc. · NCT06128551SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Phase N/A · 68 location(s) · Massive Bio, Inc. · NCT03452774A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NA · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT05837767Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Phase 2 · 22 location(s) · UNICANCER · NCT06333314Familial Investigations of Childhood Cancer Predisposition
Phase N/A · 1 location(s) · St. Jude Children's Research Hospital · NCT03050268CT-95 in Advanced Cancers Associated With Mesothelin Expression
Phase 1 · 9 location(s) · Context Therapeutics Inc. · NCT06756035Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
Phase 1/Phase 2 · 21 location(s) · Revolution Medicines, Inc. · NCT05379985MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors
Phase 1 · 2 location(s) · Memgen, Inc. · NCT05076760Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410494A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413A Study of ERAS-0015 in Patients With Advanced or Metastatic Solid Tumors
Phase 1 · 7 location(s) · Erasca, Inc. · NCT06983743SL-28 for Advanced Solid Tumours
Phase 1/Phase 2 · 1 location(s) · Second Life Therapeutics · NCT07341737A Beta-only IL-2 ImmunoTherapY Study
Phase 1/Phase 2 · 27 location(s) · Medicenna Therapeutics, Inc. · NCT05086692BBO-11818 in Adult Subjects With KRAS Mutant Cancer
Phase 1 · 17 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06917079The Cancer of the Pancreas Screening-5 CAPS5)Study
Phase 3 · 9 location(s) · Johns Hopkins University · NCT02000089EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Essen Biotech · NCT07410676A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 · 6 location(s) · Kivu Bioscience Inc. · NCT07229313Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
Phase 1 · 17 location(s) · Revolution Medicines, Inc. · NCT06040541
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.